文献速递肺结节与肺癌呼吸道感染

免疫检查点抑制剂相关结肠炎治疗中发生致命机会性感染一例

[Fatal opportunistic infection occurred during the treatment of immune checkpoint inhibitor-associated colitis:case report].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2025-01-01

本文报道1例局部晚期非小细胞肺癌患者,在化疗联合免疫治疗后出现重度ICI相关结肠炎,应用糖皮质激素及生物制剂(英夫利西单抗)治疗过程中发生血行播散性结核分枝杆菌感染和肺曲霉病,旨在提醒临床医生在处理irAE时警惕机会性感染。

要点

  • 重症irAE需糖皮质激素及生物制剂治疗。
  • 治疗期间需高度警惕机会性感染。
  • 处理irAE时应重视感染筛查与监测。

核心结论

  • 重症irAE治疗中使用糖皮质激素及生物制剂时需高度警惕机会性感染。

研究设计与样本

  • 个案报道:1例局部晚期非小细胞肺癌患者。

主要发现

  • 患者化疗联合免疫治疗后出现重度ICI相关结肠炎。
  • 应用糖皮质激素及英夫利西单抗治疗过程中发生血行播散性结核分枝杆菌感染和肺曲霉病。

临床怎么用

  • 处理irAE时,对接受糖皮质激素及生物制剂治疗的患者应警惕机会性感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitor (ICI) has been widely used in lung cancer patients. While ICI treatment improves the overall survival of patients, it can also lead to a series of immune-related adverse events (irAE). Severe irAE should be treated with glucocorticoids and biological agents. Opportunistic infections should be highly vigilant during the treatment of glucocorticoids and biological agents. We report a patient with locally advanced non-small cell lung cancer who developed severe ICI-related colitis after chemotherapy combined with immunotherapy. The patient developed hematogenous disseminated Mycobacterium tuberculosis infection and pulmonary aspergillosis during the treatment with glucocorticoids and biological agents (infliximab). The purpose of this study is to draw the attention of clinicians to opportunistic infections when dealing with irAE. 免疫检查点抑制剂(immune checkpoint inhibitor,ICI)已在肺癌中广泛应用,ICI在提高患者总生存期的同时,会导致一系列与免疫治疗相关的不良反应(immune-related adverse event,irAE)。重症irAE需要应用糖皮质激素及生物制剂治疗。糖皮质激素及生物制剂治疗过程中需高度警惕机会性感染。本文报道1例局部晚期非小细胞肺癌患者在化疗联合免疫治疗后,出现重度ICI相关结肠炎,应用糖皮质激素及生物制剂(英夫利西单抗)治疗过程中发生血行播散性结核分枝杆菌感染、肺曲霉病,旨在引起临床医生在处理irAE时对机会性感染的重视。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li YK, Tan B, Qin L, et al. [Fatal opportunistic infection occurred during the treatment of immune checkpoint inhibitor-associated colitis:case report]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40050079. doi:10.3760/cma.j.cn112147-20240920-00553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。